Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

The conversion of the convertible loan between Nexstim Plc and Bracknor

Nexstim Oyj
Posted on: 16 Sep 16


Company announcement, Helsinki, 12 January 2017 at 3 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or the " Company "), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that, pursuant to the authorisations received from the Company's Extraordinary General Meeting on 18 August 2016 and the financing arrangement entered into with Bracknor Investment which was announced on 21 July 2016, the Board of Directors of the Company has today resolved to approve Bracknor's request to convert EUR 500,000 of the convertible bond to Company's shares at issue price of EUR 0,10727. The Company has resolved to transfer a total of 4,661,135 treasury shares to Bracknor. After the transfer the Company will have 911,183 treasury shares.

After this conversion, the Company has received the full EUR 5 million funding from Bracknor based on the convertible bond facility announced on 21 July 2016 (the " CBF Agreement ") and the loan has been converted fully to shares. The SEDA arrangement between the Company and Bracknor shall continue according to the SEDA Agreement.

Martin Jamieson, Chairman & CEO

Further information is available on the website or by telephone:

Nexstim                                                                                                                                     +447715163942
Martin Jamieson, Chairman & CEO                                            
UB Securities Oy (Certified Adviser)                                                                         +358 (0)9 2538 0246

About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit


Nexstim Plc

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Nexstim Oyj via GlobeNewswire

Last updated on: 13/01/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.